Published 2020
| Version v1
Publication
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- Creators
- Bassetti, Matteo
- Vena, Antonio
- Giacobbe, Daniele Roberto
- Falcone, Marco
- Tiseo, Giusy
- Giannella, Maddalena
- Pascale, Renato
- Meschiari, Marianna
- Digaetano, Margherita
- Oliva, Alessandra
- Rovelli, Cristina
- Carannante, Novella
- Losito, Angela Raffaella
- Carbonara, Sergio
- Mariani, Michele Fabiano
- Mastroianni, Antonio
- Angarano, Gioacchino
- Tumbarello, Mario
- Tascini, Carlo
- Grossi, Paolo
- Mastroianni, Claudio Maria
- Mussini, Cristina
- Viale, Pierluigi
- Menichetti, Francesco
- Viscoli, Claudio
- Russo, Alessandro
- Others:
- Bassetti, Matteo
- Vena, Antonio
- Giacobbe, Daniele Roberto
- Falcone, Marco
- Tiseo, Giusy
- Giannella, Maddalena
- Pascale, Renato
- Meschiari, Marianna
- Digaetano, Margherita
- Oliva, Alessandra
- Rovelli, Cristina
- Carannante, Novella
- Losito, Angela Raffaella
- Carbonara, Sergio
- Mariani, Michele Fabiano
- Mastroianni, Antonio
- Angarano, Gioacchino
- Tumbarello, Mario
- Tascini, Carlo
- Grossi, Paolo
- Mastroianni, Claudio Maria
- Mussini, Cristina
- Viale, Pierluigi
- Menichetti, Francesco
- Viscoli, Claudio
- Russo, Alessandro
Description
Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy.
Additional details
- URL
- http://hdl.handle.net/11567/1016066
- URN
- urn:oai:iris.unige.it:11567/1016066
- Origin repository
- UNIGE